LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed or refractory leukemia or lymphoma.

Key facts

Study ID

NCT00085150

Run by

National Cancer Institute (NCI)

People needed

40

Starts

2004-04-01

Last updated by the study team

2015-04-30

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office — Bethesda, Maryland, United States
• Doernbecher Children's Hospital at Oregon Health & Science University — Portland, Oregon, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.